Terms: = Prostate cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
34 results:
1. Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming.
Wu Y; Clark KC; Nguyen EV; Niranjan B; Horvath LG; Taylor RA; Daly RJ
Cell Oncol (Dordr); 2022 Dec; 45(6):1311-1328. PubMed ID: 36169805
[TBL] [Abstract] [Full Text] [Related]
2. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract] [Full Text] [Related]
3. prostate cancer follow-up costs in Germany from 2000 to 2015.
Michaeli T; Michaeli D
J Cancer Surviv; 2022 Feb; 16(1):86-94. PubMed ID: 33646503
[TBL] [Abstract] [Full Text] [Related]
4. GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism.
Tong W; Qiu L; Qi M; Liu J; Hu K; Lin W; Huang Y; Fu J
J Cell Biochem; 2018 Apr; 119(4):3641-3652. PubMed ID: 29231999
[TBL] [Abstract] [Full Text] [Related]
5. High expression of pdgfr-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
[TBL] [Abstract] [Full Text] [Related]
6. Imatinib Spares cKit-Expressing prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting pdgfr-β.
Jachetti E; Rigoni A; Bongiovanni L; Arioli I; Botti L; Parenza M; Cancila V; Chiodoni C; Festinese F; Bellone M; Tardanico R; Tripodo C; Colombo MP
Mol Cancer Ther; 2017 Feb; 16(2):365-375. PubMed ID: 27980106
[TBL] [Abstract] [Full Text] [Related]
7. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment.
Watts TL; Cui R; Szaniszlo P; Resto VA; Powell DW; Pinchuk IV
J Transl Med; 2016 Dec; 14(1):337. PubMed ID: 27931212
[TBL] [Abstract] [Full Text] [Related]
8. Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Najy AJ; Dyson G; Jena BP; Lin CY; Kim HR
Am J Physiol Cell Physiol; 2016 Feb; 310(4):C293-304. PubMed ID: 26157007
[TBL] [Abstract] [Full Text] [Related]
9. Immunohistochemical expression of pdgfr, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
Kozakowski N; Hartmann C; Klingler HC; Susani M; Mazal PR; Scharrer A; Haitel A
Target Oncol; 2014 Dec; 9(4):359-66. PubMed ID: 24243494
[TBL] [Abstract] [Full Text] [Related]
10. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
Heidegger I; Massoner P; Eder IE; Pircher A; Pichler R; Aigner F; Bektic J; Horninger W; Klocker H
J Steroid Biochem Mol Biol; 2013 Nov; 138():248-56. PubMed ID: 23792785
[TBL] [Abstract] [Full Text] [Related]
11. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models.
Tahir SA; Kurosaka S; Tanimoto R; Goltsov AA; Park S; Thompson TC
Cancer Biol Ther; 2013 Feb; 14(2):117-26. PubMed ID: 23114714
[TBL] [Abstract] [Full Text] [Related]
12. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract] [Full Text] [Related]
13. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract] [Full Text] [Related]
14. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Jing C; Ning J; Yuanjie N
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2137-43. PubMed ID: 22868821
[TBL] [Abstract] [Full Text] [Related]
15. PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.
Iqbal S; Zhang S; Driss A; Liu ZR; Kim HR; Wang Y; Ritenour C; Zhau HE; Kucuk O; Chung LW; Wu D
PLoS One; 2012; 7(1):e30764. PubMed ID: 22276222
[TBL] [Abstract] [Full Text] [Related]
16. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract] [Full Text] [Related]
17. Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening pdgfr/EGFR signaling and cellular proliferation.
Farooqi AA; Bhatti S; Rana A; Fayyaz S; Mansoor Q; Javed Z; Riaz AM; Nisar K; Ahsan Qu; Dilawar BA; Asif H; Khanum R; Javeed MK
J Exp Ther Oncol; 2011; 9(3):201-6. PubMed ID: 22070051
[TBL] [Abstract] [Full Text] [Related]
18. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract] [Full Text] [Related]
20. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract] [Full Text] [Related]
[Next]
